Saturday, March 25, 2017
Breaking News

CP 55,940

cp55940CP 55,940 is Unscheduled in the United States.

Addictive Potential: Unknown

Emergency Room Visits Yearly: Unknown

Mandatory Minimum Sentence: Unknown

Mechanism of Action: Cannabinoid receptor agonist

Overview:

CP 55,940 was created by Pfizer in 1974 but was never marketed. It is 45 times more potent than Δ9-THC, and fully antagonized by rimonabant (SR141716A). CP 55,940 is considered a full agonist at both CB1 and CB2 receptors and has ki values of 0.58nM and 0.68nM respectively, but interestingly is an antagonist at GPR55, the putative “CB3” receptor. The average dose is around 0.5-1mg smoked and the effects usually last for 10-18 hours.

*View and Submit Your Experiences in the New Community Trip Reports Area*

CP 55,940 Powder

Picture of CP 55,940 Powder

 Side Effects and Adverse Reactions:

CP 55,940 is a research chemical. Research chemicals are experimental chemicals that are not approved for human consumption. This is because not enough data exists currently about their side effects, adverse reactions, long term damage, addiction potential, etc. Although some people are willing to ingest research chemicals, it is not reasonable to assume that they are in any way safe to use recreationally.

CP 55,940 and Drug Tests:

CP 55,940 is a synthetic cannabinoid that currently cannot be detected with drug tests. This is because of how drug tests work. The basic concept is that your body attempts to break down any drugs you ingest. Metabolites are formed as part of this process; testing looks for the specific types of metabolites that could only occur as a result of drug taking. There is currently (as of Nov, 2009) no test that tests for the metabolites of synthetic cannabinoids. Rumor has it that scientists are developing a drug test that tests for them, although, the development and implementation process could take years.

Research:

Binding of the non-classical cannabinoid CP 55,940, and the diarylpyrazole AM251 to rodent brain cannabinoid receptors

Characterization and distribution of binding sites for [3H]-SR 141716A, a selective brain (CB1) cannabinoid receptor antagonist, in rodent brain

Discriminative stimulus effects of CP 55,940 and structurally dissimilar cannabinoids in rats

Atypical Responsiveness of the Orphan Receptor GPR55 to Cannabinoid Ligands

Leave a Reply